Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Type II diabetes mellitus aged 19 years or older~* Subjects who performed Dual therapies (complex allowed) for one of the following, along with meals and exercise therapy~  1. Subjects who are receiving metformin ≥ 1000 mg/d and dapagliflozin 10 mg/d at the same dose for at least 8 weeks prior to the screening visit~ 2. Subjects who are receiving metformin ≥ 1000 mg/d and SGLT-2 inhibitor except for dapagliflozin at the same dose for at least 8 weeks prior to the screening visit~* Subjects with 7.0%≤HbA1c≤10.5% at screening visit~* Subjects with fasting plasma glucose ≤ 270mg/dL at screening visit~* Subjects with 18.5kg/m2≤BMI≤40kg/m2 at screening visit~Exclusion Criteria:~* Patients with type 1 diabetes, secondary diabetes, gestational diabetes, diabetic ketoacidosis, diabetic coma, pre-coma, lactic acidosis, and acute or chronic metabolic acidosis~* patients with Hypopituitarism or adrenal insufficiency, pulmonary infarction, severe pulmonary dysfunction and other hypoxemia~* Patients with severe infectious disease or severe traumatic systemic disorders~* End stage renal disease or dialysis patients~* Patients with Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption~* Subjects with Liver cirrhosis, chronic active hepatitis B or C, cholecystitis, acromegaly, asthma or major skin allergies

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Evogliptin 5mg group (Type: EXPERIMENTAL): Evogliptin 5mg/d + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d
- Evogliptin Placebo group (Type: PLACEBO_COMPARATOR): Evogliptin Placebo + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d

Based on this trial design, predict the completion outcome and termination type (if applicable).